Ibogaine for Multiple Sclerosis: What the Evidence Shows

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Immune cells cross the blood-brain barrier and attack myelin — the insulating sheath around nerve fibres — and, over time, the underlying axons. The resulting lesions disrupt conduction in the brain, optic nerves, and spinal cord.

The Atlas of MS estimates roughly 2.8–2.9 million people are living with MS worldwide. A 2019 study in Neurology using multi-payer claims data put United States prevalence at close to one million adults — more than double the previously accepted estimate. Diagnosis most often occurs between ages 20 and 40, and MS is diagnosed roughly twice as often in women as in men.

Clinicians describe several disease courses. Most people are initially diagnosed with relapsing-remitting MS (RRMS), marked by discrete attacks followed by partial or complete recovery. Many later transition to secondary progressive MS (SPMS), where disability accumulates steadily. A minority are diagnosed from the outset with primary progressive MS (PPMS).

Symptoms vary widely and can include fatigue, optic neuritis, numbness, weakness, spasticity, gait and balance impairment, bladder dysfunction, neuropathic pain, heat sensitivity, and cognitive changes.

Two facts matter for everything that follows. First, there is no cure for MS. Second, MS — particularly the relapsing form — fluctuates naturally. Lesions enlarge and shrink, inflammation and oedema resolve, and symptoms can improve spontaneously without any intervention. Any claim that a treatment produced improvement must be weighed against this background variability.

MS is comparatively well served by approved therapy. Roughly twenty disease-modifying therapies (DMTs) are licensed across major jurisdictions, supported by large randomised controlled trials.

Moderate-efficacy DMTs include interferon beta preparations, glatiramer acetate, teriflunomide, and dimethyl fumarate. High-efficacy DMTs include anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab, ublituximab), natalizumab, alemtuzumab, cladribine, and sphingosine-1-phosphate (S1P) receptor modulators (fingolimod, siponimod, ozanimod, ponesimod).

The effect sizes are real and measurable. In the pivotal OPERA I and II trials, ocrelizumab reduced the annualised relapse rate by approximately 46–47% versus interferon beta-1a. Network meta-analyses consistently place alemtuzumab, ocrelizumab, natalizumab, and fingolimod at the top for relapse control.

Where conventional medicine is genuinely weaker — and where patient frustration concentrates — is progressive disease and repair:

• Ocrelizumab is the only DMT approved for PPMS, with a modest effect: roughly a 20–30% relative reduction in confirmed disability progression
• Siponimod reduced three-month confirmed disability progression by about 21% versus placebo in SPMS
• Surveyed neurologists most frequently cite slowing progression as the greatest unmet need with current DMTs
• No remyelinating therapy is approved anywhere. Opicinumab (anti-LINGO-1), clemastine, and bexarotene each showed early promise but largely failed clinical or primary imaging endpoints

Standard care also includes corticosteroid pulses or plasma exchange for acute relapses; symptomatic treatment (dalfampridine for walking speed, baclofen or tizanidine for spasticity, agents for fatigue, bladder dysfunction, and neuropathic pain); and rehabilitation — physiotherapy, occupational therapy, and structured exercise, which carry among the most consistent functional evidence in MS care.

This is the comparison any experimental option must be measured against: an imperfect but substantial evidence base built on thousands of randomised participants.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied primarily as an experimental intervention for substance use disorders. Interest in ibogaine for multiple sclerosis is recent and driven almost entirely by mechanistic reasoning rather than clinical results.

Ibogaine has an unusually promiscuous pharmacology, interacting with NMDA receptors (as an antagonist), sigma-2 receptors, kappa- and mu-opioid receptors, nicotinic acetylcholine receptors, and the serotonin transporter. It is metabolised largely by CYP2D6 to noribogaine, an active metabolite with a long half-life that shapes both duration of effect and risk profile.

The hypothesis most often invoked for MS is neurotrophic factor upregulation:

• A 2006 FASEB Journal study (He and colleagues, Ron laboratory) showed short-term ibogaine exposure produces a sustained increase in glial cell line-derived neurotrophic factor (GDNF) via a self-reinforcing autoregulatory loop
• A 2019 Frontiers in Pharmacology study (Marton and colleagues) found that in rats, 40 mg/kg increased GDNF mRNA about 12-fold in the ventral tegmental area and 6-fold in the substantia nigra at 24 hours. BDNF mRNA rose sharply in the nucleus accumbens, though mature BDNF protein was unchanged

A second hypothesis concerns neuroinflammation — that sigma-2 activity and glial modulation might dampen pro-inflammatory signalling and indirectly permit endogenous remyelination.

The evidence-honest reading cuts against enthusiasm:

• These findings come from rodent studies of dopaminergic reward circuitry, designed to explain reduced drug and alcohol intake. They were not demyelination experiments
• GDNF's best-documented role is survival of dopaminergic neurons. Its role in oligodendrocyte precursor differentiation and myelin repair is not established
• A 2025 review in Cells examining psychedelics for MS concluded that current evidence, largely from non-specific inflammation models, is insufficient to predict clinical efficacy in an autoimmune disease like MS
• We could not identify any published study of ibogaine in experimental autoimmune encephalomyelitis (EAE) or cuprizone demyelination — the two standard rodent models used to screen candidate MS therapies. Ibogaine has essentially skipped the preclinical step MS drug development normally requires

The mechanistic story for ibogaine and remyelination is a plausible chain of inferences, not a demonstrated pathway.

As of this writing, the peer-reviewed clinical literature on ibogaine for multiple sclerosis consists of one case report describing two patients.

Chen, Inzunza Domínguez, Valle Uzeta, Pushparaj and Dickinson published "Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis" in Frontiers in Immunology in 2025.

Patient A (relapsing-remitting MS) received a 1,200 mg loading dose followed by 20 mg daily maintenance. Reported findings included a 71% reduction in lesion volume (1,659.8 mm³ to 480.5 mm³), a 35.6% decrease in mean apparent diffusion coefficient (ADC), a 92% drop in MSQLI fatigue subscores, and physical and mental component summaries up 24% and 42%.

Patient B (secondary progressive MS) received a 500 mg loading dose — the patient accepted only two of four capsules — plus 20 mg daily. Findings included cortical thickness changes, an approximately 15% decrease in ventricular volume, Hauser Ambulation Index improving from 8 to 7, and pain scores improved 73%. Follow-up ranged from three to ten months.

Those are the data. The limitations are substantial:

• n = 2. Case reports sit at the bottom of the evidence hierarchy. They are hypothesis-generating and cannot establish causation
• No control group, no blinding, no randomisation. There is no way to separate a drug effect from natural fluctuation, regression to the mean, or placebo response
• RRMS remits spontaneously by definition. Lesion volume falls as inflammation and oedema resolve. A 71% reduction in one patient over three months is not, on its own, evidence of repair
• ADC is a non-specific measure. Reduced diffusivity is consistent with remyelination but also with resolving oedema or unrelated tissue changes. Myelin-specific techniques were not the primary endpoint
• The authors' own stated limitation is that effects "cannot be confirmed to be specific to MS and may have impacted the other neuropsychiatric comorbidities"
• Author affiliation is relevant context. Co-authors include founders of the clinic that administered the treatment — a conflict of interest readers should weigh

Separately, Ambio Life Sciences announced a neuroregenerative ibogaine programme in June 2025 covering Parkinson's, MS, stroke, TBI, and ALS, reporting roughly 30 patients supported since February 2025, plus preclinical work with Dalhousie University. No outcome data from that cohort has been peer-reviewed or published. An enrolment figure is not a study result.

The frequently cited 2024 Nature Medicine study by Cherian, Williams and colleagues — magnesium–ibogaine therapy in 30 Special Operations Forces veterans — reported large improvements in disability, PTSD, depression, and anxiety with no unexpected serious adverse events. It is relevant to ibogaine's neuropsychiatric profile and protocol design, but it studied traumatic brain injury, not MS, and was open-label without a control group.

No randomised controlled trial of ibogaine for multiple sclerosis has been registered or conducted.

Independent expert reaction to the 2025 case report has been predominantly cautious. Lucid News canvassed several specialists in April 2025.

• W. Oliver Tobin, a Mayo Clinic neurologist, said the paper "has significant deficits, which renders any conclusions unsupported"
• George Robertson, a Dalhousie University pharmacology professor, framed the core problem: it is "hard to know whether this change is a drug effect or spurious remission unless you do a very long, controlled study." He described the related mitochondrial research as "encouraging but the burden of proof just isn't there"
• Jonathan Dickinson, a co-author and Ambio co-founder, was himself measured: "We're not saying we've found the cure… people in the scientific community should pay more attention"
• W. Bryan Hubbard of the American Ibogaine Initiative, an advocate for ibogaine research, cautioned that it is "best to under promise and over deliver," explicitly warning against inflated expectations among MS patients
• Juliana Mulligan, a psychotherapist working in this field, noted the evidence is unclear and that such publications risk raising false hope

Notably, the caution comes from both conventional neurology and from within the ibogaine research and advocacy community. That convergence is the most honest summary of where the field stands: a signal worth investigating, and nothing that justifies acting as though the question is settled.

Because ibogaine is Schedule I in the United States, people seeking it typically travel to clinics in jurisdictions where it is unscheduled or tolerated — most commonly Mexico, and also Costa Rica and Portugal. Regulatory oversight varies widely, and none of these programmes are approved MS treatments.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, plus cardiology clearance for any abnormality
• Echocardiogram in programmes treating higher-risk populations
• Comprehensive metabolic panel with serum potassium and magnesium, corrected to normal range before dosing
• Liver and renal function testing, and full blood count
• Complete medication and supplement reconciliation, screening for QT-prolonging and serotonergic agents
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure

The protocol described in the 2025 case report included pre-treatment magnesium and vitamin infusions, lactulose afterward, 24-hour nursing with vitals every 30 minutes, and continuous cardiac monitoring for the first 12 hours.

One caveat deserves emphasis: 12 hours of telemetry is shorter than several cardiac safety reviews recommend. Noribogaine's half-life is roughly 28–49 hours, QT prolongation after ibogaine typically lasts more than 24 hours, and documented adverse cardiac events have occurred 12 to 76 hours after dosing.

The acute experience involves several hours of intense psychoactive effects followed by extended recovery, commonly with profound ataxia, nausea, vomiting, and inability to stand or walk unassisted for many hours.

For a person with MS, that raises considerations generic protocols do not address: pre-existing gait and balance impairment compounded by drug-induced ataxia; aspiration risk during vomiting for anyone with swallowing difficulty; heat sensitivity and Uhthoff's phenomenon; and pre-existing autonomic dysfunction, which is common in MS and has been proposed as a contributing mechanism in ibogaine-associated sudden deaths.

Ibogaine's safety profile is dominated by one issue: cardiac electrophysiology. This is not theoretical, and it is not resolved by a careful setting alone.

The mechanism. Ibogaine and noribogaine block hERG potassium channels in cardiomyocytes. Koenig and Hilber (Molecules, 2015) report an IC50 of approximately 4 µM for ibogaine and 3 µM for noribogaine — concentrations reached at therapeutic doses. hERG blockade prolongs repolarisation, lengthening the QT interval and raising the risk of torsades de pointes, ventricular tachycardia, and cardiac arrest.

The magnitude. QTc values of 480–700 ms have been documented in clinical case reports. A QTc above 500 ms is generally regarded as conferring substantial arrhythmia risk.

The outcomes. Between 1990 and 2008, 19 fatalities were temporally associated with ibogaine ingestion, six from acute cardiac complications; subsequent reviews document further deaths. Case reports show these events occur at therapeutic doses and in people without pre-existing cardiac disease.

Documented risk factors include:

• Hypokalaemia — present in 100% of reported fatality cases in the Koenig and Hilber review, in some instances as low as 2 mmol/L
• Hypomagnesaemia — present in roughly half of cases
• Concurrent hERG-blocking drugs — methadone, cocaine, alcohol
• CYP2D6 poor-metaboliser status, prolonging noribogaine exposure
• Bradycardia, female sex, and structural heart disease

Considerations specific to people with MS. These are areas where general ibogaine safety data intersects with MS care and where, in most cases, no interaction data exist at all:

• S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod) slow heart rate and require first-dose cardiac monitoring; some carry QT-related labelling. Combining them with a potent hERG blocker is a serious, entirely unstudied risk
• Recent corticosteroid pulses for relapse management can lower serum potassium — the single most consistent factor in ibogaine fatalities
• Antidepressants and neuropathic pain agents common in MS (SSRIs, SNRIs, tricyclics) carry both serotonergic-interaction and QT-prolongation concerns
• Baclofen and tizanidine add sedation and hypotension
• Anti-CD20 and other immunosuppressive DMTs raise infection risk in non-hospital settings
• MS-related dysautonomia may compound the autonomic instability implicated in ibogaine deaths

Generally accepted absolute contraindications include known long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, pregnancy, and active psychosis or bipolar I disorder.

Finally, nothing is known about the safety of the 20 mg daily maintenance dosing described in the case report over months or years. Chronic low-dose exposure to a hERG-blocking compound has not been characterised in any published safety study.

Legal status. Ibogaine is a Schedule I controlled substance under the United States Controlled Substances Act — the most restrictive category, denoting high abuse potential, no currently accepted medical use, and lack of accepted safety under medical supervision. It is not approved for multiple sclerosis anywhere in the world.

The policy landscape is shifting: Texas has committed substantial state funding toward FDA-directed ibogaine clinical trials, and several states have introduced research legislation. But registered ibogaine trials to date target substance use disorder and neuropsychiatric conditions — not MS.

What would actually advance the question of ibogaine for multiple sclerosis:

• Preclinical work in MS-specific models. EAE and cuprizone studies would establish whether ibogaine affects autoimmune demyelination at all. Their absence is the largest single gap
• Myelin-specific imaging — magnetisation transfer ratio or myelin water fraction — to distinguish genuine remyelination from resolving inflammation, which ADC cannot do
• A prospective registry with standardised outcomes. People are already travelling for treatment; systematically collecting EDSS, standardised MRI, and adverse events with blinded raters would generate far better data than scattered case reports
• Controlled trial design. Blinding an intensely psychoactive drug is difficult — an active comparator or dose-comparison design would be needed
• Interaction studies with DMTs, particularly S1P modulators
• Durability and chronic-dosing safety data, and whether immune modulation could worsen autoimmunity — none of which has been examined

The honest bottom line. The evidence for ibogaine in multiple sclerosis consists of two published cases, rodent neurotrophic findings from unrelated brain circuits, and a mechanistic hypothesis untested in any MS model. Set against that is a well-documented, potentially fatal cardiac risk and specific interaction concerns for people on MS medications. Scientists on both sides of this debate — including some sympathetic to ibogaine research — describe the current evidence as insufficient to support clinical conclusions.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about MS treatment — including whether to start, continue, or stop a disease-modifying therapy — should be made with a treating neurologist. Discontinuing a DMT can precipitate disease rebound, which for some agents is severe.